KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 58 filers reported holding KALVISTA PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $103,407 | +3346.9% | 10,738 | +5735.9% | 0.01% | – |
| Q4 2019 | $3,000 | +50.0% | 184 | +166.7% | 0.00% | – |
| Q2 2019 | $2,000 | -90.0% | 69 | -90.1% | 0.00% | -100.0% |
| Q1 2019 | $20,000 | +66.7% | 697 | +16.8% | 0.00% | 0.0% |
| Q4 2018 | $12,000 | -20.0% | 597 | -9.0% | 0.00% | 0.0% |
| Q3 2018 | $15,000 | +87.5% | 656 | -36.6% | 0.00% | 0.0% |
| Q2 2018 | $8,000 | +166.7% | 1,034 | +244.7% | 0.00% | – |
| Q1 2018 | $3,000 | – | 300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 422,310 | $10,849,000 | 5.86% |
| COMMODORE CAPITAL LP | 214,467 | $5,510,000 | 2.20% |
| Vivo Capital, LLC | 1,863,296 | $47,868,000 | 1.68% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 214,533 | $5,486,000 | 1.45% |
| Nicholas Investment Partners, LP | 594,130 | $15,263,000 | 1.06% |
| Altium Capital Management LP | 128,130 | $3,292,000 | 0.91% |
| Affinity Asset Advisors, LLC | 100,000 | $2,569,000 | 0.87% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,000 | $1,285,000 | 0.70% |
| APIS CAPITAL ADVISORS, LLC | 30,000 | $771,000 | 0.70% |
| Birchview Capital, LP | 40,000 | $1,028,000 | 0.61% |